| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2019.08.003 |
| P698 | PubMed publication ID | 31443991 |
| P2093 | author name string | Lei Zhang | |
| Guihua Zhuang | |||
| Mingwang Shen | |||
| Ruyi Xia | |||
| Shuliu Sun | |||
| P2860 | cites work | Hepatitis E epidemic, Uganda | Q24609019 |
| Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 | Q27860791 | ||
| Case-fatality risk of pregnant women with acute viral hepatitis type E: a systematic review and meta-analysis | Q30251843 | ||
| Clinical profile, maternal and fetal outcomes of acute hepatitis e in pregnancy | Q34092748 | ||
| Discovery of hepatitis E: the epidemic non-A, non-B hepatitis 30 years down the memory lane. | Q34164503 | ||
| Epidemiology of hepatitis E virus in China: results from the Third National Viral Hepatitis Prevalence Survey, 2005-2006 | Q34434631 | ||
| Long-term efficacy of a hepatitis E vaccine. | Q34465637 | ||
| Direct economic burden of hepatitis B virus related diseases: evidence from Shandong, China. | Q34569561 | ||
| Hepatitis e vaccine to prevent morbidity and mortality during epidemics | Q35072039 | ||
| A preliminary cost-effectiveness analysis of hepatitis E vaccination among pregnant women in epidemic regions | Q37197088 | ||
| Cost-effectiveness thresholds: pros and cons | Q37498173 | ||
| WHO Guide for standardisation of economic evaluations of immunization programmes | Q37536433 | ||
| Fetal and neonatal health consequences of vertically transmitted hepatitis E virus infection | Q37573028 | ||
| Clinical presentation of hepatitis E. | Q37860521 | ||
| Making the case for the development of a vaccination against hepatitis E virus. | Q38212391 | ||
| Annual economic burden of hepatitis B virus-related diseases among hospitalized patients in twelve cities in China | Q38932361 | ||
| Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. | Q39009825 | ||
| Evaluation of rapid tests for diagnosis of acute hepatitis E. | Q39956914 | ||
| Performance of an antigen assay for diagnosing acute hepatitis E virus genotype 3 infection | Q40731184 | ||
| Modeling the long-term antibody response of a hepatitis E vaccine. | Q40781273 | ||
| Financial burden on the families of patients with hepatitis B virus-related liver diseases and the role of public health insurance in Yunnan province of China | Q40989879 | ||
| Recommendations of the Panel on Cost-effectiveness in Health and Medicine | Q41145868 | ||
| Hepatitis E vaccine: WHO position paper, May 2015--Recommendations | Q41523791 | ||
| Direct economic burden and influencing factors in patients with hepatitis B virus related diseases in Jiangsu, China | Q42180934 | ||
| Seroprevalence of hepatitis E virus among pregnant women and control subjects in China | Q42197112 | ||
| Protection against hepatitis E virus infection by naturally acquired and vaccine-induced immunity | Q42244598 | ||
| Hepatitis E virus seroprevalence and molecular study among blood donors in China | Q42246567 | ||
| Diagnostic performance of selected commercial HEV IgM and IgG ELISAs for immunocompromised and immunocompetent patients | Q42256720 | ||
| Performance of anti-HEV assays for diagnosing acute hepatitis E in immunocompromised patients | Q42258240 | ||
| Disease burden of foodborne pathogens in the Netherlands, 2009. | Q43015262 | ||
| Safety of the hepatitis E vaccine for pregnant women: a preliminary analysis | Q43974663 | ||
| Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial | Q45189946 | ||
| The global burden of hepatitis E virus genotypes 1 and 2 in 2005. | Q45361424 | ||
| Maternal and fetal outcomes in pregnant women with acute hepatitis E virus infection | Q45402345 | ||
| Hepatitis E virus infection and fulminant hepatic failure during pregnancy | Q45404977 | ||
| CT coronary angiography in patients suspected of having coronary artery disease: decision making from various perspectives in the face of uncertainty. | Q53326954 | ||
| Hepatitis E | Q56656388 | ||
| High Mortality Associated with an Outbreak of Hepatitis E among Displaced Persons in Darfur, Sudan | Q56830163 | ||
| Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy* | Q59829993 | ||
| A cost-effectiveness analysis of universal childhood hepatitis A vaccination in China | Q81572029 | ||
| Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine | Q83235565 | ||
| Hepatitis E vaccine: why wait? | Q85016201 | ||
| P433 | issue | 39 | |
| P921 | main subject | hepatitis E | Q326643 |
| P304 | page(s) | 5868-5876 | |
| P577 | publication date | 2019-08-20 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Targeted hepatitis E vaccination for women of childbearing age is cost-effective in China | |
| P478 | volume | 37 |
Search more.